Back to top
more

Arcus Biosciences (RCUS)

(Delayed Data from NYSE)

$17.39 USD

17.39
424,485

+0.42 (2.47%)

Updated Sep 12, 2024 04:00 PM ET

After-Market: $17.40 +0.01 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GSK Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix and Juluca to drive fourth-quarter sales.

Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why

by Zacks Equity Research

Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.

Amarin Corporation (AMRN) Down 13% in One Week: Here's Why

by Zacks Equity Research

Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.

Seagen's (SGEN) Tukysa Gets Accelerated FDA Nod for New Indication

by Zacks Equity Research

The FDA grants accelerated approval to Seagen's (SGEN) Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer.

Angion (ANGN) Down on Merger Agreement With Private Biotech

by Zacks Equity Research

Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.

Roche (RHHBY) Gets EU Approval for Xofluza in New Patient Base

by Zacks Equity Research

The European Commission approves Roche's (RHHBY) Xofluza for treating uncomplicated influenza and post-exposure prophylaxis of influenza in children aged one year and above.

Down -45.21% in 4 Weeks, Here's Why Arcus Biosciences, Inc. (RCUS) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Arcus Biosciences, Inc. (RCUS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Ekta Bagri headshot

Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More

by Ekta Bagri

Pipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week.

Gilead (GILD), RCUS Announce Positive Data From NSCLC Study

by Zacks Equity Research

Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).

Wall Street Analysts Believe Arcus Biosciences, Inc. (RCUS) Could Rally 45%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 44.5% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 75% Upside in Arcus Biosciences, Inc. (RCUS): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 75% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks.com featured highlights Chimerix, Vista Oil & Gas and Arcus Biosciences

by Zacks Equity Research

Chimerix, Vista Oil & Gas and Arcus Biosciences have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

Buy 3 of the Best Stocks by Using Net Income Ratio

by Tirthankar Chakraborty

Chimerix (CMRX), Vista Oil & Gas (VIST) and Arcus Biosciences (RCUS) have been selected as the top picks with a high net income ratio.

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 14.29% and 83.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss

by Zacks Equity Research

Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.

Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Strength Seen in Arvinas, Inc. (ARVN): Can Its 12% Jump Turn into More Strength?

by Zacks Equity Research

Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Can Arcus Biosciences, Inc. (RCUS) Climb 75% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 74.8% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 0% and 27.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down

by Zacks Equity Research

Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -215.66% and 88.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of -41.18% and 8.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (RCUS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 428.32% and 3,898.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?

by Zacks Equity Research

Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.

Gilead (GILD) Exercises Options to Three Arcus Programs

by Zacks Equity Research

Gilead (GILD) exercises options to Arcus' anti-TIGIT Program (domvanalimab and AB308), etrumadenant (A2a/A2b Adenosine Receptor Antagonist), and quemliclustat (small Molecule CD73 Inhibitor).